Menu Search
Equities

Ondine Biomedical Inc

VF5:DEU

Ondine Biomedical Inc

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year Ondine Biomedical Inc grew revenues 88.56% from 638.00k to 1.20m while net income improved from a loss of 19.37m to a smaller loss of 14.41m.
Gross margin58.44%
Net profit margin-1,198.01%
Operating margin-1,230.67%
Return on assets-129.24%
Return on equity-209.95%
Return on investment-193.37%
More ▼

Cash flow in CADView more

In 2023, cash reserves at Ondine Biomedical Inc fell by 10.13m. Cash Flow from Financing totalled 3.79m or 314.63% of revenues. In addition the company used 13.65m for operations while cash used for investing totalled 177.00k.
Cash flow per share-0.0389
Price/Cash flow per share--
Book value per share0.0051
Tangible book value per share0.0051
More ▼

Balance sheet in CADView more

Ondine Biomedical Inc has a Debt to Total Capital ratio of 20.60%, a higher figure than the previous year's 8.74%.
Current ratio1.36
Quick ratio1.06
Total debt/total equity0.2595
Total debt/total capital0.206
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.